Main Article Content


Methyldopa is the first-line drugs to treat hypertension in pregnancy. It can decrease blood pressure in preeclampsia by affecting a2-adrenoreceptors in central nervous system. However, it could also act by decreasing  production of sFlt-1 antiangiogenic protein levels involved in the pathophysiology of hypertention  in preeclampsia. The purpose of this study was to analyze methyldopa therapy on sFlt-1 antiangiogenic levels in the plasma of pregnant women with severe preeclampsia at the Obstetric Departement, Haji Hospital, Surabaya. This was a prospective study with observational cross-section study design. The sFlt-1 angiogenic levels were observed before and after (48 hours) methyldopa administration in severe preeclampsia patient with or without complications in the period of August to October 2016. Patient received methyldopa 250 mg or 500 mg, three times a day for clinical indications according a standard protocol. The study was approved by the ethical committee of Haji Hospital, Surabaya. There were 19 patients with preeclampsia who met the inclusion criteria, showed a decrease in the levels of sFlt-1 before and 48 hours after methyldopa therapy. Levels of sFlt-1 before methyldopa therapy in a dose of 250 mg was 10.15±10.00 (2.55-34.70) ng/ml and after therapy 8,37±9,20 (0.72-9.20) ng/ml, with a percentage decrease 17.54%. sFlt-1 levels before methyldopa therapy in a dose of 500 mg was 8.05±7.07 (2.55-20.76) ng/ml, after  therapy 4.50±2.90 (2.19-9.95) ng/ml, with a percentage decrease 44.16%. Methyldopa therapy could decrease sFlt-1 levels of antiangiogenic factor in patients with severe preeclampsia.


Methyldopa severe preeclampsia antiangiogenic soluble fms-like tyrosine kinase (sFlt-1)

Article Details

How to Cite
Herwati, T. W., Yulistiani, Y., & M, E. Z. (2018). Analysis of Methyldopa Therapy on sFlt-1 Antiangiogenic Levels in Patients with Severe Preeclampsia. Folia Medica Indonesiana, 54(1), 46–52.


  1. Angsar MD (2010). Hipertensi dalam kehamilan. In S. Prawirohardjo, Ilmu Kebidanan. Jakarta, PT. Bina Pustaka Sarwono Prawirohardjo, p 530-50
  2. Cunningham F, et al (2010). Williams Obstetric. 23th ed. New York, McGraw-Hill Education
  3. Davison J, et al (2004). New Aspects in Patho-physiology of Preeclampsia. Journal of the American Society of Nephrology 15, 2440-2448
  4. Day MD, et al (1973). The mechanism of the a enti-hypertensive action of methyldopa in hypertensive rats. Eur J Pharmacol 21, 271-280
  5. Hattori Y, Yamamoto S, Matsuda N (2007). Sympa-thetic control of VEGF angiogenic signaling. Circula-tion Research 101, 642-4
  6. Henning M, Rubenson A (1971) Evidence that the hypotensive action of methyldopa is mediated by central actions of methylnoradrenaline. J Pharm Phar-macol 23, 407-11
  7. Kahlil A (2008). Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factor in pregnancies with hypertensive disorders. Plos ONE 6, 5-21
  8. Levine RJ, et al (2004). Circulating angiogenic factors and the risk of preeclampsia. The New England Journal Medicine 350, 672-683
  9. Maynard SE (2003). Excess placental soluble Fms-like tyrosine kinase 1 (sFlt-1) may contribute to endho-telial dysfunction, hypertension, and proteinuria I preeclampsia. J The Journal of Clinical Investigation 111, 649-658
  10. Maynard SE, et al (2003). Soluble Fms-like tyrosine kinase 1 and endothelial disfunction in the patho-genesis of preeclampsia. Department of Medicine 57, 5
  11. Zhang Z, et al (2012). Hypoxia-induce factor-1 alpha signaling: Regulation of vascular endothelial growth factor-dependent angiogenesis during ovarian corpus luteum development in mammals. Journal of Vete-rinary Medicine and Animal Health 4, 97-104

Most read articles by the same author(s)

1 2 > >>